Efexor XL licence extended

Efexor XL (venlafaxine) is now indicated in moderate to severe generalised social anxiety disorder/social phobia in adults.

Efexor is also indicated in major depressive disorder and in moderate to severe generalised anxiety disorder. The recommended dose in social anxiety disorder is 75mg once daily.

If the patient has failed to respond after 12 weeks, alternative therapy should be considered. Continuation of treatment in a responding patient can be considered on an individual basis, but there is no evidence of efficacy beyond six months.


Further information: Wyeth 0845 3670098

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Logo of the webinar

Cow's Milk Allergy in Practice: free webinar series for UK healthcare professionals

Join us for a short webinar series offering insights...

Close up image of multicoloured capsules

MIMS antidepressants table updated

The MIMS table 'Antidepressants, a guide to switching...

Purple, orange, blue and yellow blood test tubes on a tray.

New advice on vitamin B12 monitoring in patients taking metformin

Patients on metformin treatment with risk factors for...